Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis

V. Cepero, J. R. Sierra, S. Giordano

Research output: Contribution to journalArticle

Abstract

During the last decades, the improvement of our knowledge of the mechanisms responsible for cancer development has led to the introduction of new promising strategies of treatment, based on "molecular targeted" drugs. These drugs are designed to act on specific molecules, identified as major players in the maintenance of the malignant status. The development of inhibitors, mainly monoclonal antibodies and small-molecules, directed against activated oncogenes has been the most widely used approach for this kind of treatment. Among the oncogenes implicated in human cancers, tyrosine kinases play a critical role. This observation, together with the discovery that cancer cells can be dependent for their survival from the continuous expression of activated oncogenes (a concept defined as "oncogene addiction"), has made protein kinases ideal targets for targeted therapy in cancer. As the field of targeted therapies is now rapidly growing and a comprehensive survey would be too wide, this review will thus mainly focus on strategies aimed at inhibiting tyrosine kinases and their signal transduction pathways.

Original languageEnglish
Pages (from-to)1396-1409
Number of pages14
JournalCurrent Pharmaceutical Design
Volume16
Issue number12
Publication statusPublished - Apr 2010

Fingerprint

Oncogenes
Protein-Tyrosine Kinases
Neoplasm Metastasis
Neoplasms
Pharmaceutical Preparations
Protein Kinases
Signal Transduction
Monoclonal Antibodies
Maintenance
Survival
Therapeutics

Keywords

  • Cancer therapy
  • Kinase inhibitors
  • Monoclonal antibodies
  • Targeted therapies
  • Tyrosine kinase

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis. / Cepero, V.; Sierra, J. R.; Giordano, S.

In: Current Pharmaceutical Design, Vol. 16, No. 12, 04.2010, p. 1396-1409.

Research output: Contribution to journalArticle

@article{98082a627af3479fb3f87f62f31a210c,
title = "Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis",
abstract = "During the last decades, the improvement of our knowledge of the mechanisms responsible for cancer development has led to the introduction of new promising strategies of treatment, based on {"}molecular targeted{"} drugs. These drugs are designed to act on specific molecules, identified as major players in the maintenance of the malignant status. The development of inhibitors, mainly monoclonal antibodies and small-molecules, directed against activated oncogenes has been the most widely used approach for this kind of treatment. Among the oncogenes implicated in human cancers, tyrosine kinases play a critical role. This observation, together with the discovery that cancer cells can be dependent for their survival from the continuous expression of activated oncogenes (a concept defined as {"}oncogene addiction{"}), has made protein kinases ideal targets for targeted therapy in cancer. As the field of targeted therapies is now rapidly growing and a comprehensive survey would be too wide, this review will thus mainly focus on strategies aimed at inhibiting tyrosine kinases and their signal transduction pathways.",
keywords = "Cancer therapy, Kinase inhibitors, Monoclonal antibodies, Targeted therapies, Tyrosine kinase",
author = "V. Cepero and Sierra, {J. R.} and S. Giordano",
year = "2010",
month = "4",
language = "English",
volume = "16",
pages = "1396--1409",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "12",

}

TY - JOUR

T1 - Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis

AU - Cepero, V.

AU - Sierra, J. R.

AU - Giordano, S.

PY - 2010/4

Y1 - 2010/4

N2 - During the last decades, the improvement of our knowledge of the mechanisms responsible for cancer development has led to the introduction of new promising strategies of treatment, based on "molecular targeted" drugs. These drugs are designed to act on specific molecules, identified as major players in the maintenance of the malignant status. The development of inhibitors, mainly monoclonal antibodies and small-molecules, directed against activated oncogenes has been the most widely used approach for this kind of treatment. Among the oncogenes implicated in human cancers, tyrosine kinases play a critical role. This observation, together with the discovery that cancer cells can be dependent for their survival from the continuous expression of activated oncogenes (a concept defined as "oncogene addiction"), has made protein kinases ideal targets for targeted therapy in cancer. As the field of targeted therapies is now rapidly growing and a comprehensive survey would be too wide, this review will thus mainly focus on strategies aimed at inhibiting tyrosine kinases and their signal transduction pathways.

AB - During the last decades, the improvement of our knowledge of the mechanisms responsible for cancer development has led to the introduction of new promising strategies of treatment, based on "molecular targeted" drugs. These drugs are designed to act on specific molecules, identified as major players in the maintenance of the malignant status. The development of inhibitors, mainly monoclonal antibodies and small-molecules, directed against activated oncogenes has been the most widely used approach for this kind of treatment. Among the oncogenes implicated in human cancers, tyrosine kinases play a critical role. This observation, together with the discovery that cancer cells can be dependent for their survival from the continuous expression of activated oncogenes (a concept defined as "oncogene addiction"), has made protein kinases ideal targets for targeted therapy in cancer. As the field of targeted therapies is now rapidly growing and a comprehensive survey would be too wide, this review will thus mainly focus on strategies aimed at inhibiting tyrosine kinases and their signal transduction pathways.

KW - Cancer therapy

KW - Kinase inhibitors

KW - Monoclonal antibodies

KW - Targeted therapies

KW - Tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=77950911519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950911519&partnerID=8YFLogxK

M3 - Article

C2 - 20166985

AN - SCOPUS:77950911519

VL - 16

SP - 1396

EP - 1409

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 12

ER -